Is Pregnancy Characteristic Associated with Ovarian Cancer? A Review of the Available Evidence
Numerous epidemiological studies examining the etiology of ovarian cancer and the role of pregnancy related factors in ovarian cancer has been one of the topics of interest to many researchers. Various articles have only mentioned the link between some risk factors and ovarian cancer, but no study has addressed the various dimensions of this issue to this day. Therefore, due to the important position of ovarian cancer among gynecological cancers, this study was conducted to investigate the pregnancy-related risk factors for ovarian cancer.
To determine the relationship between pregnancy characteristic and ovarian cancer, a comprehensive search was carried out in English databases such as; Medline, Web of Science Core Collection, and Scopus using keywords; pregnancy, ovarian cancer (or 'carcinoma of the ovary' or 'ovarian neoplasm' or 'ovarian tumor'), risk factor, pregnancy characteristic terms and a combination of these terms. Full-text, English language, and original articles were included in this study. In total, 35 articles were entered into the study. The relationship between pregnancy related factors and ovarian cancer were studied. Although there was a weak association between some factors such as preterm birth and the risk of ovarian cancer, only the strong protective effect of parity was seen in the articles.
The results of this study did not show that pregnancy related factors increase the risk of ovarian cancer. In summary, the findings are inadequate regarding some risk factors such as gender of fetus, multiple pregnancy, placental and fetal weight, parity, miscarriage, preeclampsia, and gestational diabetes, and raised questions for future research.
1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. International Journal of Cancer 2021. [CrossRef]
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians 2018;68:284–96. [CrossRef]
3. Sopik V, Iqbal J, Rosen B, Narod SA. Why have ovarian cancer mortality rates declined? Part I. Incidence. Gynecologic oncology 2015;138:741–9. [CrossRef]
4. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. International journal of women's health 2019;11:287. [CrossRef]
5. Vachon CM, Mink PJ, Janney CA, Sellers TA, Cerhan JR, Hartmann L, et al. Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a populationbased study of postmenopausal women. Epidemiology (Cambridge, Mass) 2002;13:66–71. [CrossRef]
6. Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective M zillion Women Study. International journal of cancer 2018;142:281–9. [CrossRef]
7. Fathalla M. Incessant ovulation and ovarian cancer–a hypothesis re-visited. Facts, views & vision in ObGyn 2013;5:292.
8. Fathalla M. Incessant ovulation—a factor in ovarian neoplasia. Lancet 1971;2:163. [CrossRef]
9. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute 1983;71:717–21.
10. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111–7.
11. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute 1998;90:1774– 86. [CrossRef]
12. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International journal of surgery (London, England) 2010;8:336–41. [CrossRef]
13. Adami H-O, Lambe M, Persson I, Ekbom A, Hsieh C, Trichopoulos D, et al. Parity, age at first childbirth, and risk of ovarian cancer. The Lancet 1994;344:1250–4. [CrossRef]
14. Albrektsen G, Heuch I, Kvåle G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: a Norwegian prospective study. British journal of cancer 1997;75:767–70. [CrossRef]
15. Albrektsen G, Heuch I, Thoresen S, Kvåle G. Twin births, sex of children and maternal risk of ovarian cancer: a cohort study in Norway. British journal of cancer 2007;96:1433–5. [CrossRef]
16. Baik I, Lambe M, Liu Q, Chie L, Cnattingius S, Mucci LA, et al. Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort. Cancer Causes & Control 2008;19:1131–7. [CrossRef]
17. Baik I, Lambe M, Liu Q, Cnattingius S, Mucci LA, Riman T, et al. Gender of offspring and maternal risk of invasive epithelial ovarian cancer. Cancer Epidemiology and Prevention Biomarkers 2007;16:2314–20. [CrossRef]
18. Bodelon C, Wentzensen N, Schonfeld S, Visvanathan K, Hartge P, Park Y, et al. Hormonal risk factors and invasive epithelial ovarian cancer risk by parity. British journal of cancer 2013;109:769–76. [CrossRef]
19. Braem MG, Onland-Moret NC, Schouten LJ, Kruitwagen RF, Lukanova A, Allen NE, et al. Multiple miscarriages are associated with the risk of ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition. PloS one 2012;7:e37141. [CrossRef]
20. Calderon-Margalit R, Friedlander Y, Yanetz R, Deutsch L, Perrin MC, Kleinhaus K, et al. Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. American journal of obstetrics and gynecology 2009;200:63. e1–. e5. [CrossRef]
21. Chen M-T, Cook LS, Daling JR, Weiss NS. Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes & Control 1996;7:415–20. [CrossRef]
22. Cnattingius S, Eloranta S, Adami H-O, Axelsson O, Dickman PW, Hsieh C-c, et al. Placental weight and risk of invasive epithelial ovarian cancer with an early age of onset. Cancer Epidemiology and Prevention Biomarkers 2008;17:2344–9. [CrossRef]
23. Fu Z, Moysich K, Ness RB, Modugno F. Gender of offspring and risk of ovarian cancer: The HOPE study. Cancer epidemiology 2020;64:101646. [CrossRef]
24. Fuchs O, Sheiner E, Meirovitz M, Davidson E, Sergienko R, Kessous R. The association between a history of gestational diabetes mellitus and future risk for female malignancies. Archives of gynecology and obstetrics 2017;295:731–6. [CrossRef]
25. Gierach GL, Modugno F, Ness RB. Relations of gestational length and timing and type of incomplete pregnancy to ovarian cancer risk. American journal of epidemiology 2005;161:452–61. [CrossRef]
26. Gierach GL, Modugno F, Ness RB. Gender of offspring and maternal ovarian cancer risk. Gynecologic oncology 2006;101:476–80. [CrossRef]
27. Han K-T, Cho GJ, Kim EH. Evaluation of the association between gestational diabetes mellitus at first pregnancy and cancer within 10 years postpartum using National health insurance data in South Korea. Int J Environ Res Public Health 2018;15:2646. [CrossRef]
28. Ji J, Forsti A, Sundquist J, Hemminki K. Risks of breast, endometrial, and ovarian cancers after twin births. Endocrine-related cancer 2007;14:703–11. [CrossRef]
29. Jordan SJ, Green AC, Nagle CM, Olsen CM, Whiteman DC, Webb PM, et al. Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. American journal of epidemiology 2009;170:607–14. [CrossRef]
30. McGuire V, Hartge P, Liao LM, Sinha R, Bernstein L, Canchola AJ, et al. Parity and oral contraceptive use in relation to ovarian cancer risk in older women. Cancer Epidemiology and Prevention Biomarkers 2016;25:1059–63. [CrossRef]
31. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine 2001;345:235–40. [CrossRef]
32. Mogren HS, Ulf Högberg, Ingrid. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta oncologica 2001;40:849–54. [CrossRef]
33. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. American journal of epidemiology 2008;167:1059–69. [CrossRef]
34. Mucci LA, Dickman PW, Lambe M, Adami H-O, Trichopoulos D, Riman T, et al. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiology and Prevention Biomarkers 2007;16:1828–32. [CrossRef]
35. Negri E, Franceschi S, La Vecchia C, Parazzini F. Incomplete pregnancies and ovarian cancer risk. Gynecologic oncology 1992;47:234–8. [CrossRef]
36. Peng Y-S, Lin J-R, Cheng B-H, Ho C, Lin Y-H, Shen C-H, et al. Incidence and relative risk for developing cancers in women with gestational diabetes mellitus: a nationwide cohort study in Taiwan. BMJ open 2019;9:e024583. [CrossRef]
37. Sieh W, Sundquist K, Sundquist J, Winkleby MA, Crump C. Intrauterine factors and risk of nonepithelial ovarian cancers. Gynecologic oncology 2014;133:293–7. [CrossRef]
38. Sköld C, Bjørge T, Ekbom A, Engeland A, Gissler M, Grotmol T, et al. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. International journal of cancer 2018;143:1858–67. [CrossRef]
39. Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakær J, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiology and Prevention Biomarkers 2007;16:1160–6. [CrossRef]
40. Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Risk factors for epithelial ovarian cancer in women under age 45. European Journal of Cancer 1993;29:1297–301. [CrossRef]
41. Titus-Ernstoff L, Perez K, Cramer D, Harlow B, Baron J, Greenberg E. Menstrual and reproductive factors in relation to ovarian cancer risk. British journal of cancer 2001;84:714–21. [CrossRef]
42. Tung K-H, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. American Journal of Epidemiology 2003;158:629–38. [CrossRef]
43. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiology and Prevention Biomarkers 2003;12:42–6.
44. Wu AH, Pearce CL, Lee AW, Tseng C, Jotwani A, Patel P, et al. Timing of births and oral contraceptive use influences ovarian cancer risk. International journal of cancer 2017;141:2392–9.
45. Yang C-Y, Kuo H-W, Chiu H-F. Age at first birth, parity, and risk of death from ovarian cancer in Taiwan: a country of low incidence of ovarian cancer. International Journal of Gynecologic Cancer 2007;17. [CrossRef]
46. Danzer H, Braunstein GD, Rasor J, Forsythe A, Wade ME. Maternal serum human chorionic gonadotropin concentrations and fetal sex prediction. Fertility and sterility 1980;34:336–40.
47. Bremme K, Eneroth P, Nilsson B, Marsk L, Hagenfeldt L. Outcome of pregnancy in relation to maternal serum alpha-fetoprotein levels in the second trimester. Gynecologic and obstetric investigation 1988;26:191–205. [CrossRef]
48. Chen R-J, And Y-HL, Huang S-C. Fetal sex and maternal alpha-fetoprotein concentration at late normal singleton pregnancies. Acta obstetricia et gynecologica Scandinavica 1994;73:192–4. [CrossRef]
49. Chellakooty M, Skibsted L, Skouby SO, Andersson A-M, Petersen JH, Main KM, et al. Longitudinal study of serum placental GH in 455 normal pregnancies: correlation to gestational age, fetal gender, and weight. The Journal of Clinical Endocrinology & Metabolism 2002;87:2734–9. [CrossRef]
50. Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med 2018;283:430–45. [CrossRef]
51. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 2005;161:321–9. [CrossRef]
52. Greer JB, Modugno F, Ness RB, Allen GO. Anthropometry and the risk of epithelial ovarian cancer. Cancer 2006;106:2247– 57. [CrossRef]
53. Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001:307–12.
54. Obiekwe BC, Chard T. Human chorionic gonadotropin levels in maternal blood in late pregnancy: relation to birthweight, sex and condition of the infant at birth. British journal of obstetrics and gynaecology 1982;89:543–6. [CrossRef]
55. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. The Lancet Oncology 2005;6:103– 11. [CrossRef]
56. Mabjeesh N, Chen J, Beri A, Stenger A, Matzkin H. Sexual function after permanent 125 I-brachytherapy for prostate cancer. International journal of impotence research 2005;17:96–101.
57. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS medicine 2009;6:e1000201. [CrossRef]
58. Han KH, Kim M-K, Kim HS, Chung HH, Song YS. Protective Effect of Progesterone during Pregnancy against Ovarian Cancer. J Cancer Prev 2013;18:113–22. [CrossRef]
59. Chen T, Surcel H-M, Lundin E, Kaasila M, Lakso H-A, Schock H, et al. Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer. Cancer Epidemiology and Prevention Biomarkers 2011;20:324–36. [CrossRef]
60. Schock H, Surcel H-M, Zeleniuch-Jacquotte A, Grankvist K, Lakso H-Å, Fortner RT, et al. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocrine-related cancer 2014;21:831–44. [CrossRef]